Fresenius Medical Care AG

As of June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR carries a market capitalization of 62.04B, placing it among publicly traded companies globally. Its enterprise value stands at 123.98B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR's next confirmed earnings release is scheduled for November 3, 2026.

As of June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR has 514.25M shares outstanding.

As of June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR trades at a trailing price-to-earnings ratio of 10.32. The price-to-sales ratio is 0.50, and the price-to-book ratio stands at 0.84.

As of June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR trades at an EV/EBITDA multiple of 6.21 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.08 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.52 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR trades at an EV/FCF ratio of 10.06, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 123.98B versus a market cap of 62.04B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR maintains a current ratio of 1.07, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 81.02, indicating elevated leverage, while an interest coverage ratio of 8.82 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR posted a return on equity (ROE) of 7.26, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 5.74 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 3.00, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 3.98, useful for judging operating efficiency across full business cycles. The company generates approximately 1.03M in revenue per employee across its workforce of 111,728.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 6.61 indicates how many times Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR recorded 1.86B in income tax expense. That works out to an effective tax rate of 20.93, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 8.87B, leaving 5.54B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 15, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR's stock has declined approximately 14.43% over the past 52 weeks. The 50-day moving average sits at 122.99, while the 200-day moving average is 111.20.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR generated 114.73B in revenue and converted that into 5.54B in net income, yielding earnings per share of 14.80. EBITDA reached 19.96B, while operating income came in at 11.60B.

As of June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR holds 8.56B in cash and equivalents against 64.74B in total debt, resulting in a net debt position of 38.41B. Total book value stands at 74.15B, with working capital of 3.02B providing operational flexibility.

Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR produced 16.71B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -6.18B in capital expenditures, free cash flow totaled 10.54B - equivalent to 22.24 per share.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR posted a gross margin of 26.36, reflecting its pricing power and cost economics. The operating margin of 10.11 and net profit margin of 4.83 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR paid dividends of - - per share. The dividend payout ratio of - - indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 18.44, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 24.26, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR shareholders.

As of June 30, 2026, Fresenius Medical Care AG ADR Unsponsored Brazilian Depositary Receipt Repr 1 ADR has an Altman Z-Score of 3.06, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.